Silexion Therapeutics has moved SIL204 into active patient treatment, beginning a multinational Phase 2/3 study that will evaluate the RNAi candidate alongside standard chemotherapy in locally advanced pancreatic cancer.
Key Investor Takeaways
- Silexion Therapeutics (NASDAQ:SLXN) has successfully dosed the first patient in its Phase 2/3 SIL204 trial, moving the programme into active clinical execution.
- The study will begin with a safety run-in of approximately 18 patients before expanding to a randomized cohort of around 166 patients.
- SIL204 is being evaluated as a first-line treatment alongside standard chemotherapy in newly diagnosed patients with unresectable Stage 3 locally advanced pancreatic cancer and confirmed KRAS mutations.
- Additional trial sites in Israel and Germany are progressing toward activation, providing the basis for broader patient enrolment.
- Preliminary clinical readouts are planned in the near term, making initial safety and efficacy findings the next major data point for the programme.
Why SLXN Stock Is in Focus
Silexion has dosed the first patient worldwide in its Phase 2/3 clinical trial of SIL204, marking the transition of its lead second-generation RNA interference candidate into active patient treatment.
The prospective, randomized and controlled multinational study compares SIL204 plus standard-of-care chemotherapy with chemotherapy alone in patients with locally advanced pancreatic cancer.
The programme starts with a safety run-in involving approximately 18 patients before expanding to an approximately 166-patient randomized cohort. Eligible patients are newly diagnosed, treatment-naïve adults with unresectable Stage 3 disease, no distant metastases and a confirmed KRAS mutation.
SIL204 uses two delivery routes. It is administered directly into the pancreatic tumor through an endoscopic ultrasound-guided procedure, while subcutaneous abdominal injections are intended to provide systemic exposure and address potential micro-metastases.
Why This Matters for Investors
First-patient dosing is primarily an execution milestone rather than evidence of clinical efficacy. For Silexion, however, it moves SIL204 from trial preparation into the stage where patient safety and treatment outcomes can begin generating clinical evidence.
The Phase 2/3 structure also creates a defined development pathway. Successful completion of the initial safety cohort could allow the company to move into the larger randomized portion of the study, where SIL204’s performance can be compared with chemotherapy alone.
The dual-route administration strategy is another important element of the programme. Silexion designed the approach to combine direct delivery into the primary tumor with systemic exposure, but the trial will need to establish whether that strategy translates into acceptable safety and improved clinical outcomes.
Expansion beyond the initial Israeli site may also affect the pace of enrolment. Additional oncology centres in Israel and academic institutions in Germany are moving through activation, according to the company.
What to Watch Next
The immediate focus will be enrolment and safety findings from the approximately 18-patient run-in cohort, followed by progress toward the randomized expansion phase. Investors will also be watching for activation of additional Israeli and German sites and the preliminary clinical readouts referenced by Silexion, particularly data relating to response rates and survival outcomes.